Inherited Renal Tubulopathies Associated With Metabolic Alkalosis: Effects on Blood Pressure

Seminars in Nephrology

Volumn 26, Issue 6, 2006, Pages 422-433

  Ariceta, Gema ^a   Rodríguez Soriano, Juan ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

hypertension; metabolic alkalosis; potassium; tubulopathy

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; CALCIUM; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; NIMESULIDE; POTASSIUM CHLORIDE; POTASSIUM DIHYDROGEN PHOSPHATE; SPIRONOLACTONE; TRIAMTERENE;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; BARTTER SYNDROME; BLOOD PRESSURE MEASUREMENT; BSND GENE; CALCIUM URINE LEVEL; CLCNKB GENE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GENE; GENE FUNCTION; GENE MUTATION; GITELMAN SYNDROME; HUMAN; HYPERCALCIURIA; HYPERTENSION; HYPOKALEMIA; KCNJ1 GENE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DISORDER; LIDDLE SYNDROME; METABOLIC ALKALOSIS; MONOTHERAPY; NEPHRON; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT LOSING NEPHRITIS; SLC12A1 GENE; SNCC1B GENE; SNCC1G GENE; SYMPTOM;

ALDOSTERONE; ALKALOSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; HUMANS; HYPOKALEMIA; POTASSIUM; PROGNOSIS; RENAL TUBULAR TRANSPORT, INBORN ERRORS;

EID: 33846583698     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.10.002     Document Type: Article

References (136)

1. Koeppen B.M., and Stanton B.A. Renal Physiology. (ed 3) (2001), Mosby, Inc, Philadelphia, PA
2. Rodriguez Soriano J. Tubular disorders of electrolyte regulation. In: Avner E.D., Harmon W.E., and Niaudet P. (Eds). Pediatric Nephrology. (ed 5) (2004), Lippincott, William & Wilkins, Baltimore, MD 729-756
3. Greger R. Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron. Physiol Rev 65 (1985) 760-797
4. Hebert S.C. An ATP-regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Kidney Int 48 (1995) 1010-1016
5. Ellison D.H. Divalent cation transport by the distal nephron: Insights from Bartter's and Gitelman's syndromes. Am J Physiol 279 (2000) F616-F625
6. Biner H.L., Arpin-Bott M.P., Loffing J., et al. Human cortical distal nephron: Distribution of electrolyte and water transport pathways. J Am Soc Nephrol 13 (2002) 836-847
7. Waldegger S., and Jentsch T.J. Functional and structural analysis of ClC-K chloride channels involved in renal disease. J Biol Chem 275 (2000) 24527-24533
8. Estevez R., Boettger T., Stein V., et al. Barttin is a Cl-channel beta-subunit crucial for renal Cl-reabsorption and inner ear K+ secretion. Nature 414 (2001) 558-561
9. Naray-Fejes-Toth A., Canessa C., Cleaveland E.S., et al. Sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial Na+ channels. J Biol Chem 274 (1999) 16973-16978
10. Naray-Fejes-Toth A., and Fejes-Toth G. 11 beta-hydroxysteroid dehydrogenase in renal collecting duct cells. Steroids 59 (1994) 105-110
11. Lang F., Capasso G., Schwab M., et al. Renal transport and the genetic basis of hypertensive disease. Clin Exp Nephrol 9 (2005) 91-99
12. Lifton R.P., Gharavi A.G., and Geller D.S. Molecular mechanisms of human hypertension. Cell 104 (2001) 545-556
13. Rodríguez Soriano J. Bartter and related syndromes: The puzzle is almost solved. Pediatr Nephrol 12 (1998) 315-327
14. Rodríguez Soriano J. Potassium homeostasis and its disturbances in children. Pediatr Nephrol 9 (1995) 364-374
15. Sojo A., Rodríguez Soriano J., Vitoria J.C., et al. Chloride deficiency as a presentation or complication of cystic fibrosis. Eur J Pediatr 153 (1994) 825-828
16. Hebert S.C. Bartter síndrome. Curr Opin Nephrol Hypertens 12 (2003) 527-532
17. Bartter F.C., Pronove P., Gill Jr. J.R., et al. Hyperplasia of juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med 33 (1962) 811-818
18. Proesmans W. Bartter syndrome and its neonatal variant. Eur J Pediatr 156 (1997) 669-679
19. Seyberth H.W., Rascher W., Schweer W., et al. Congenital hypokalemia with hypercalciuria in preterm infants: A hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr 107 (1985) 694-701
20. Simon D.B., Karet F.E., Hamdan J.M., et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13 (1996) 183-188
21. Vargas-Poussou R., Feldmann D., Vollmer M., et al. Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome. Am J Hum Genet 62 (1998) 1332-1340
22. Bettinelli A., Ciarmatori S., Cesareo L., et al. Phenotypic variability in Bartter syndrome type I. Pediatr Nephrol 14 (2000) 940-945
23. International Collaborative Study Group for Bartter-like Syndromes. Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: Evidence for genetic heterogeneity. Hum Mol Genet 6 (1997) 17-26
24. ir 1.1 (ROMK) in neonatal Bartter syndrome. Pediatric Nephrol 12 (1997) 69-71
25. Jeck N., Derst C., Wischmeyer E., et al. Functional heterogeneity of ROMK mutations linked to hyperprostaglandin E syndrome. Kidney Int 69 (2001) 1803-1811
26. Starremans P.G.J.F., Ersten F.F.J., Knoers N.V.A.M., et al. Mutations in the human Na-K-2Cl cotransporter (NKCC2) identified in Bartter syndrome type I consistently result in nonfunctional transporters. J Am Soc Nephrol 14 (2003) 1419-1426
27. + channel, ROMK. Nat Genet 14 (1996) 152-156
28. Starremans P.G.J., van der Kemp A.W.C.M., Knoers N.V.A.M., et al. Functional implications of mutations in the human renal outer medullary potassium channel (ROMK2) identified in Bartter syndrome. Pflugers Arch 443 (2002) 466-472
29. ir 1.1) channels: Control by an arg-lys-arg triad disrupted in antenatal Bartter syndrome. Proc Natl Acad Sci U S A 96 (1999) 15298-15303
30. Feldman D., Alessandri J.-L., and Deschênes G. Large deletion of the 5′ end of the ROMK1 gene causes antenatal Bartter syndrome. J Am Soc Nephrol 9 (1998) 2357-2359
31. Peters M., Ermert S., Jeck N., et al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 64 (2003) 923-932
32. Vollmer M., Jeck N., Lemmink H.H., et al. Antenatal Bartter syndrome with sensorineural deafness: Refinement of the locus on chromosome 1p31. Nephrol Dial Transplant 15 (2000) 970-974
33. Birkenhäger R., Otto E., Schürman M., et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29 (2001) 310-314
34. Hayama A., Rai T., Sasaki S., et al. Molecular mechanisms of Bartter syndrome caused by mutations in the BSND gene. Histochem Cell Biol 119 (2003) 485-493
35. Konrad M., Vollmer M., Lemmink H.H., et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 11 (2000) 1449-1459
36. Schlingmann K.P., Konrad M., Jeck K., et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 350 (2004) 1314-1319
37. Matsumura Y., Uchida S., Kondo Y., et al. Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel. Nat Genet 21 (1999) 95-98
38. + channel function. Biochem Biophys Res Commun 230 (1997) 641-645
39. Macica C.M., Yang Y., Hebert S.C., et al. Arachidonic acid inhibits activity of cloned renal K+ channel, ROMK1. Am J Physiol 271 (1996) F588-F594
40. Köckerling A., Reinalter S.C., and Seyberth H.W. Impaired response to furosemide in hyperprostaglandin E syndrome: Evidence for a tubular defect in the loop of Henle. J Pediatr 129 (1996) 519-528
41. 2 EP4 receptor in furosemide-induced salt-losing tubulopathy: A model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol 16 (2005) 2354-2362
42. Rodríguez Soriano J., Vallo A., and Aguirre M. Bone mineral density and bone turnover in patients with Bartter syndrome. Pediatr Nephrol 20 (2005) 1120-1125
43. Proesmans W., Massa G., Vanderberghe K., et al. Prenatal diagnosis in Bartter syndrome. Lancet 1 (1987) 394
44. Matsushita Y., Suzuki Y., Oya N., et al. Biochemical examination of the mother's urine is useful for prenatal diagnosis of Bartter syndrome. Prenat Diagn 19 (1999) 671-673
45. 2 syndrome after genetic diagnosis from amniocytes. Pediatrics 103 (1999) 678-683
46. Filer G., Shalev H., Bilk O.S., et al. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr 142 (2003) 318-323
47. Rodriguez Soriano J., Vallo A., and Garcia-Fuentes M. Hypomagnesemia of hereditary renal origin. Pediatr Nephrol 1 (1987) 465-472
48. Langhendries J.P., Thiry V., Bodart E., et al. Exogenous prostaglandin administration and pseudo-Bartter syndrome. Eur J Pediatr 149 (1989) 208-209
49. Rodríguez Soriano J. Bartter's syndrome comes of age. Pediatrics 13 (1999) 663-664
50. Jeck N., Reinalter B.C., Henne T., et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 108 (2001) E5
51. Shalev H., Ohali M., Kachko L., et al. The neonatal variant of Bartter syndrome and deafness: Preservation of renal function. Pediatrics 112 (2003) 628-633
52. Komhoff M., Jeck N.D., Seyberth H.W., et al. Cyclooxygenase 2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 58 (2000) 2420-2424
53. Nusing R.M., Reinalter S.C., Peterts M., et al. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: Therapeutic use of cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 70 (2001) 384-390
54. Reinalter S.C., Jeck N., Brochhausen C., et al. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 62 (2002) 253-260
55. Bettinelli A., Bianchetti M.G., Girardin E., et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr 120 (1992) 38-43
56. Caló L., Davis P.A., Milani M., et al. Bartter's syndrome and Gitelman's syndrome: Two entities sharing the same abnormality in vascular reactivity. Clin Nephrol 50 (1998) 65-67
57. Caló L., Davis P.A., Milani M., et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 51 (1999) 12-17
58. Calò L.A. Vascular tone control in humans: Insights from studies in Bartter's/Gitelman's syndromes. Kidney Int 69 (2006) 963-966
59. Simon D.B., Bindra R.S., Nelson-Williams C., et al. Mutations in the chloride channel ClC-Kb cause Bartter's syndrome type III. Nat Genet 17 (1997) 171-178
60. Jeck N., Konrad M., Peters M., et al. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res 48 (2000) 754-758
61. Zelikovic I., Szargel R., Hawash A., et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int 63 (2003) 24-32
62. Rodríguez Soriano J., Vallo A., Pérez de Nanclares G., et al. A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain. Pediatr Nephrol 20 (2005) 891-896
63. Bettinelli A., Borsa N., Syrén M.-L., et al. Simultaneous mutations in the CLCNKB and SLC12A3 genes in two siblings with phenotypic heterogeneity in classic Bartter syndrome. Pediatr Res 58 (2005) 1269-1273
64. Vargas-Poussou R., Huang C., Hulin P., et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13 (2002) 2259-2266
65. Watanabe S., Fukumoto S., Chang H., et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360 (2002) 692-694
66. Jeck N., Waldegger S., Lampert A., et al. Activating mutation ofn the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension 43 (2004) 1175-1181
67. Rodríguez-Soriano J., Vallo A., Castillo G., et al. Renal handling of water and sodium in infancy and childhood: A study using clearance methods during hypotonic saline diuresis. Kidney Int 20 (1981) 700-704
68. Hené R.J., Koomans H.A., and Dorhout M.E.J. Suppressed diluting segment reabsorption in Bartter's syndrome: Studies in 1 patient and synthesis of literature. Am J Nephrol 8 (1988) 402-409
69. Emma F., Pizzini C., Tessa A., et al. "Bartter-like" phenotype in Kearns-Sayre síndrome. Pediatr Nephrol 21 (2006) 355-360
70. Güllner M.G., Gill Jr. J.R., Bartter F.C., et al. A familial disorder with hypokalemic alkalosis, hyperreninemia, aldosteronism, high urinary prostaglandins and normal blood pressure that is not "Bartter's syndrome.". Trans Assoc Am Physicians 92 (1979) 175-178
71. Güllner H.G., Bartter F.C., Gill Jr. J.R., et al. A sibship with hypokalemic alkalosis and renal proximal tubulopathy. Arch Intern Med 143 (1983) 1534-1540
72. Colussi G., Rambolá G., Airaghi C., et al. Pseudo-Bartter's syndrome from subreptitious diuretic intake: Differential diagnosis with true Bartter's syndrome. Nephrol Dial Transplant 7 (1992) 896-901
73. D'Avanzo M., Santinelli R., Tolone C., et al. Concealed administration of furosemide simulating Bartter's syndrome in a 4.5 year-old boy. Pediatr Nephrol 9 (1995) 749-750
74. Arant B., Brackett N., Young R., et al. Case studies of siblings with juxtaglomerular hyperplasia and secondary hyperaldosteronism associated with severe azotemia and renal rickets-Bartter's syndrome or disease. Pediatrics 46 (1970) 344-361
75. Gitelman H.J., Graham J.B., and Welt L.G. A new familial disorder characterized by hypokaliemia and hypomagnesemia. Trans Assoc Am Physicians 79 (1966) 221-223
76. Ea H.K., Blanchard A., Dougados M., et al. Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. J Rheumatol 32 (2005) 1840-1842
77. Gupta R., Hu V., Reynolds T., et al. Sclerochoroidal calcification associated with Gitelman syndrome and calcium pyrophosphate dihydrate deposition. J Clin Pathol 58 (2005) 1334-1335
78. Cruz D.N., Shaer A.J., Bia M.J., and Yale Gitelman's and Bartter's Syndrome Collaborative Study. Gitelman's syndrome revisited: An evaluation of symptoms and health-related quality of life. Kidney Int 59 (2001) 710-717
79. Simon D.B., Nelson-Williams C., Bia M.J., et al. Gitelman's variant of Bartter syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12 (1996) 24-30
80. Ryan M.P. Diuretics and potassium/magnesium depletion. Am J Med 82 suppl 3A (1987) 38-47
81. Peters M., Jeck N., Reinalter S.S., et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing nephropathies. Am J Med 112 (2002) 183-190
82. Knoers N.V.A.M., Jong de J.C., Meij I.C., et al. Genetic renal disorders with hypomagnesemia and hypocalciuria. J Nephrol 16 (2003) 293-296
83. Coto E., Rodríguez J., Jeck N., et al. A new mutation (intron 9+1G>T) in the SLC12A3 gene is linked to Gitelman syndrome in Gypsies. Kidney Int 65 (2004) 25-29
84. Lin S.-H., Chian J.-C., Huang C.-C., et al. Phenotype and genotype analysis in Chinese patients with Gitelman's syndrome. J Clin Endocrinol Metab 90 (2005) 2500-2507
85. De Jong J.C., van der Vliet W.A., van der Heuvel L.P.W.J., et al. Functional expression of mutations in the human NaCl cotransport: Evidence for impaired routing mechanisms in Gitelman's syndrome. J Am Soc Nephrol 13 (2002) 1442-1448
86. Nijenhuis T., Vallon V., van der Kemp A.W.C.M., et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 115 (2005) 1651-1658
87. Quamme G.A. Renal magnesium handling: New insights in understanding old problems. Kidney Int 52 (1997) 1180-1195
88. Ljunghall S., Backman U., Danielson B.G., et al. Calcium and magnesium metabolism during long-term treatment with thiazides. Scand J Urol Nephrol 15 (1981) 257-262
89. Dai L.J., Friedman P.A., and Quamme G.A. Cellular mechanisms of chlorothiazide and potassium depletion on Mg2+ in mouse distal convoluted cells. Kidney Int 51 (1997) 1008-1017
90. Rouffinac de C., and Quamme G. Renal magnesium handling and its hormonal control. Physiol Rev 74 (1994) 305-322
91. Solomon R. The relationship between disorders of K and Mg homeostasis. Semin Nephrol 7 (1987) 253-262
92. Laine J., Jalanko H., Alakulppi, et al. A new tubular disorder with hypokalaemic metabolic alkalosis, severe hypomagnesaemia, hypercalciuria and cardiomyopathy. Nephrol Dial Trasplant 20 (2005) 1241-1245
93. Schepkens H., Hoeben H., Vanholder R., et al. Mimicry of surreptitious diuretic ingestion and the ability to make a genetic diagnosis. Clin Nephrol 55 (2001) 233-237
94. Ariceta G., Rodríguez Soriano J., Vallo A., et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28 (1997) 35-40
95. Barakat A.J., and Rennert O.M. Gitelman's syndrome (familial hypokalemia-hypomagnesemia). J Nephrol 14 (2001) 43-47
96. Ariceta G., and Rodríguez Soriano J. Magnesium. In: Grimble G.K., Predddy V.R., and Watson R.R. (Eds). Nutrition and the infant: Practice and procedures (2001), Greenwich Medical Media, Ltd, Cambridge, UK 149-158
97. Dyckner T., Wester P., and Widman L. Amiloride prevents thiazide-induced intracellular potassium and magnesium losses. Acta Med Scand 224 (1988) 25
98. Cortesi C., Foglia P.E.G., Bettinelli A., et al. Prevention of cardiac arrhythmias in pediatric patients with normotensive-hypokalemic tubulopathy. Pediatr Nephrol 18 (2003) 729-730
99. Bettinelli A., Tosetto C., Colussi G., et al. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int 62 (2002) 580-584
100. Yiu V.W.Y., Dluhy R., Lifton R.P., et al. Low peripheral plasma renin activity (PRA) as a critical marker in pediatric hypertension. Pediatr Nephrol 11 (1997) 343-346
101. Scheinman S.J., Guay-Woddford L.M., Thakker R.V., et al. Genetic disorders of renal electrolyte transport. N Engl J Med 15 (1999) 1177-1187
102. Liddle G.W., Bledsoe T., and Coppage W.S. A familial renal disorder simulating primary hyperaldosteronism but with negligible aldosterone secretion. Trans Am Assoc Physicians 76 (1963) 199-213
103. Botero-Velez M., Curtis J.J., and Warnock D.G. Liddle's syndrome revisited-a disorder of sodium reabsorption in the distal tubule. N Engl J Med 330 (1994) 178-181
104. Warnock D.G. Liddle syndrome: Genetics and mechanisms of Na+ channel defects. Am J Med Sci 322 (2001) 302-307
105. Shimkets R.A., Warnock D.G., Bositis C.M., et al. Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79 (1994) 407-414
106. Hansson J.H., Nelson-Williams C., Suzuki H., et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: Genetic heterogeneity of Liddle's syndrome. Nat Genet 11 (1995) 76-82
107. Vallon V., and Lang F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr Opin Nephrol Hypertens 14 (2005) 59-66
108. Abriel H., Loffing J., Rebhun J.F., et al. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. J Clin Invest 103 (1999) 667-673
109. Snyder P.M., Olson D.R., McDonald F.J., et al. Multiple WW domains, but not the C2 domain, are required for inhibition of the epithelial Na+ channel by human Nedd4. J Biol Chem 276 (2001) 28321-28326
110. + channel. FASEB J 15 (2001) 204-214
111. Wong Z.Y.H., Stebbing M., Ellis J.A., et al. Genetic linkage of β and γ subunits of epithelial sodium channel to systolic blood pressure. Lancet 353 (1999) 1222-1225
112. Su Y.R., Rutkowski M.P., Klanke C.A., et al. A novel variant of the b-subunit of the amiloride-sensitive sodium channel in African Americans. J Am Soc Nephrol 7 (1996) 2543-2549
113. Smith P.R., and Benos D.J. Epithelial Na+ channels. Annu Rev Physiol 53 (1999) 509-530
114. New M.I., Levine E.G., Biglieri E.G., et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 44 (1977) 924-933
115. Monder C., Shackleton C.H.L., Bradlow H.L., et al. The syndrome of apparent mineralocorticoid excess: its association with 11-beta-dehydrogenase and 5-bet-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 63 (1986) 550-557
116. White P.C., Mune T., and Agarwal A.K. 11 β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18 (1997) 135-156
117. Wilson R.C., Krozowski Z.S., Li K., et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80 (1995) 2263-2266
118. Wilson R.C., Dave-Sharma S., Wei J.Q., et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A 95 (1998) 10200-10205
119. Moudgil A., Rodich G., Jordan S.C., et al. Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess. Pediatr Nephrol 15 (2000) 60-62
120. Agarwal A.K., Rogerson F.M., Mune T., et al. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11-beta-hydroxysteroid dehydrogenase. Genomics 29 (1995) 195-199
121. Funder J.W., Pearce P.T., Smith R., et al. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 242 (1988) 583-585
122. New M.I. Hypertension in congenital adrenal hyperplasia and apparent mineralocorticoid excess. Ann N Y Acad Sci 970 (2002) 145-154
123. Dave-Sharma A.S., Wilson R.C., Harbison M.D., et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 83 (1998) 2244-2254
124. Walker B.R., and Edwards C.R. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 23 (1994) 359-377
125. Burgio E., Zammardi E., Vierucci A., et al. Un caso di pseudoiperaldosteronismo da ingestione di liquirizia. Riv Ital Pediatr 6 (1980) 391-392
126. Palermo M., Delitala G., Sorba G., et al. Does kidney transplantation normalize cortisol metabolism in apparent mineralocorticoid excess syndrome?. J Endocrinol Invest 23 (2000) 457-462
127. Geller D.S., Farhi A., Pinkerton N., et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289 (2000) 119-123
128. Stowasser M., and Gordon R.D. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78 (2001) 215-229
129. McMahon G.T., and Dluby R. Glucocorticoid-remediable aldosteronism. Cardiol Rev 12 (2004) 44-48
130. Sutherland D.J., Ruse J.L., and Laidlaw J.C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. CMAJ 95 (1966) 1109-1119
131. Gordon R.D. Heterogeneous hypertension. Nat Genet 11 (1995) 6-9
132. Lifton R.P., Dluhy R.G., Powers M., et al. A chimeric 11-beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 (1992) 262-265
133. Lifton R.P., Dluhy R.G., Powers M., et al. Hereditary hypertension caused by chimeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 2 (1992) 6-74
134. Litchfield W.R., New M.I., Coolidge C., et al. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82 (1997) 3570-3573
135. Dluhy R.G., Anderson B., Harlin B., et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 138 (2001) 715-720
136. Kater C.E., and Biglieri E.G. The syndromes of low-renin hypertension: "Separating the wheat from the chaff.". Arq Bras Endocrinol Metabol 48 (2004) 674-681